Dr. Daniel Latham, Novartis - Qepler Summits And Conferences

Dr. Daniel Latham

Head – Device Development & LCM, Device Development & Commercialisation
Basel, Switzerland

Daniel Latham is the Head of Device Development & LCM, where he leads an organisation of around 120 associates responsible for the development and life cycle management of delivery systems of drug/device combinations for both new biologic entities, biosimilars, and new chemical entities.

Over the past 11 years at Novartis, he has overseen significant device and primary packaging developments and launches and has significantly supported the growth of device development and drug/device interaction within the organisation.

Prior to Novartis, he worked in a variety of roles in consumer health¬care, focusing on the development of OTC medicines, transdermal patches, and medical devices.

He has a Ph.D. in controlled drug delivery from Queen Mary, Uni¬versity of London and a bachelor’s degree and master’s degrees in engineering from the University of Sheffield.

Related Sessions:

Drug/Device Combination
Products Summit 2018

Get up to date with the regulatory and quality compliance strategies for combination product development.
  • 04 Dec 2018
  • Berlin, DE
  • Pharma
Day 1: Tuesday, 04 December 2018
CASE STUDY: Using the delivery system concept to streamline drug/device combination approval in EU in accordance with MDR and article 117 requirements.
  • Delivery system concept in pharma and managing future complexity
  • Delivery system platforms and set up
  • Strategies for streamlining approval of drug/device combinations in EU with respect to introduction of MDR and article 117
View Details

Pre-Filled Syringes
Summit 2018

Enhance a fully integrated system approach for developing pre-filled syringes to maintain patient centricity.
  • 31 May 2018
  • Berlin, DE
  • Pharma
Day 1: Thursday, 31 May 2018
CASE STUDY: Developing delivery systems comprising pre-filled syringes and injection devices.
  • Combination products and delivery systems – reducing development risk.
  • Importance of understanding the design space of a delivery system.
  • Considerations for setting up platforms for delivery systems.
View Details